Explaining clinically important variability in response to simvastatin treatment using a PBPK/PD approach

Area of Science:

• Pharmacology
• Pharmacokinetics
• Systems Biology

Background:

• Optimal simvastatin (SV) dosing balances efficacy and safety, but plasma levels don't always reflect intrahepatic exposure of the active form, simvastatin hydroxy acid (SVA).
• Hepatocyte uptake via OATP1B1 transporter (SLCO1B1) and metabolism by CYP3A4 influence SVA pharmacokinetics.
• Obesity and Roux-en-Y gastric bypass (RYGB) surgery can alter drug disposition and enzyme activity, affecting hepatic drug exposure.

Purpose of the Study:

• To evaluate gene-drug and disease-drug interactions affecting SVA pharmacokinetics.
• To optimize SV dosing by linking intrahepatic unbound SVA concentration to LDL-cholesterol (LDL-C) reduction.
• To utilize a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling approach.

Main Methods:

• Physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling was employed.
• Simulations were conducted across various doses, SLCO1B1 genotypes, and populations.
• The study linked intrahepatic unbound SVA concentration to LDL-C reduction.

Main Results:

• SLCO1B1 c.521T>C variation impacted plasma SVA exposure but not hepatic SVA exposure.
• Obese individuals showed higher plasma and hepatic SVA exposure compared to non-obese individuals.
• A 20 mg SV dose achieved 30-49% LDL-C reduction in obese subjects regardless of SLCO1B1 genotype, while non-obese subjects may need 40 mg.

Conclusions:

• Systemic drug concentration and SLCO1B1 genotyping alone are insufficient for predicting statin response.
• Integrating genetic and physiological variability into a PBPK/PD framework is crucial for optimizing SV doses.
• Personalized dosing strategies are needed for diverse populations to achieve optimal simvastatin efficacy and safety.